Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

As GLP-1 Drug Shortage Ends, Why Will Patients Pay More?

by October 11, 2024
October 11, 2024
As GLP-1 Drug Shortage Ends, Why Will Patients Pay More?

Jeffrey A. Singer

People who have taken high school economics should know about the law of supply and demand. Put simply, if demand for a good or service rises relative to supply, the price for the good or service increases. Conversely, if the supply of the good or service exceeds demand, the price drops. When supply and demand equilibrate, the price stabilizes. This is a spontaneous, self-directed market phenomenon that Adam Smith metaphorically called an “invisible hand.” But a visible hand—a Food and Drug Administration rule that governs pharmacists who compound drugs—may soon mean that patients will pay more for obesity-reducing GLP‑1 drugs as the supply increases.

Under the Food, Drug and Cosmetic Act of 1938 and subsequent amendments, compounding pharmacists do not need FDA approval to make and sell their products to consumers provided they use FDA-approved ingredients from FDA-approved manufacturing facilities. However, the agency prohibits compounding pharmacies from producing a drug that “essentially copies a commercially available drug.” The FDA waives this prohibition during critical shortages of a commercially available product.

When clinical studies demonstrated that GLP‑1 drugs (e.g., semaglutide, tirzepatide), developed to treat diabetes, are effective weight loss drugs that directly act on the brain’s satiety center to reduce food intake (also drink less alcohol and smoke fewer cigarettes) doctors began prescribing them to help reduce the health risks associated with obesity. The FDA approved semaglutide (Wegovy) for chronic weight loss in adults in 2021. Demand for GLP-1s dramatically increased. In late 2022, the FDA officially announced a shortage of tirzepatide, semaglutide, and other GLP-1s, and permitted compounding pharmacies to make essential copies of them. Compounding pharmacies expanded patient’s access to these excellent drugs at much lower prices than they would have paid for commercially manufactured versions.

On October 2, the FDA announced that the supply of tirzepatide had caught up with demand and removed it from its drug shortage list. Other GLP-1s remain on the FDA shortage list. For many people who are benefitting from tirzepatide, this means they will go back to paying more for the commercially available product. The higher prices may cause some people to stop taking the drug altogether. FDA compounding regulations explain why, counterintuitively, consumers will be paying higher prices for GLP-1s as supply improves.

Compounding pharmacies are considering workarounds, such as compounding products with doses or delivery systems that are slightly different from the commercially available drugs.

One way to improve the situation would be for the FDA to remove barriers to compounding pharmacies making products that are essential copies of commercially available products. Drug makers might bring lawsuits against compounding pharmacies for patent infringement, but this would not be an issue with off-patent drugs.

A better approach would be for the FDA to reclassify GLP-1s as over-the-counter drugs, which could drive prices down as producers compete for comparison-shopping customers.

Notwithstanding FDA drug compounding regulations and prescription requirements, there is already a thriving grey market in GLP‑1 drugs. Some of these products contain toxic impurities or are phony knockoffs. If the FDA ends the prescription requirement for GLP-1s, it will deal a blow to the grey market and make it easier and safer for patients to access these important drugs.

0
FacebookTwitterGoogle +Pinterest
previous post
Forecasting vs Budgeting: How Financial Models Differ in Business Planning
next post
New Ships Offer a Case Study in Protectionist Dysfunction

You may also like

Should the Fed Devalue Our Currency to Implement...

July 29, 2022

Congress Has Questions about California High-Speed Rail

June 3, 2024

Corporate Welfare and Low-Income Welfare

May 8, 2025

Autonomy and Affordability: Solving Homelessness Without Coercion

December 13, 2024

How the Market of Tech Platforms Uncovered Potential...

July 30, 2024

Follow Up on Bank Secrecy Act Data

June 5, 2023

Biden Administration Again Delays Decision on Banning Menthol...

April 29, 2024

Treating Business Costs Correctly in the Tax Code

September 5, 2024

Did the Tax Cuts and Jobs Act Pay...

July 31, 2024

Steve Ballmer’s New Public Sector 10‑K Report Illustrates...

April 20, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • SCOOP: Blue state Republican could oppose Trump tax bill over Medicaid changes

      June 28, 2025
    • Marco Rubio holds first meeting with families of hostages held by Hamas

      June 28, 2025
    • Trump’s NATO Turnaround: From threatening to pull US out to ‘daddy’ of the alliance

      June 28, 2025
    • Week Ahead: As NIFTY Breaks Out, Change Of Leadership Likely To Keep The Index Moving

      June 28, 2025
    • Trump’s ‘big, beautiful bill’ faces Republican family feud as Senate reveals its final text

      June 28, 2025
    • Senate shuts down Kaine’s attempt to check Trump’s war powers

      June 28, 2025

    Categories

    • Business (8,329)
    • Investing (2,081)
    • Politics (15,846)
    • Stocks (3,177)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved